MARKET

SNDX

SNDX

Syndax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.05
-0.70
-3.08%
Opening 10:29 12/02 EST
OPEN
22.51
PREV CLOSE
22.75
HIGH
22.51
LOW
21.52
VOLUME
32.95K
TURNOVER
--
52 WEEK HIGH
23.98
52 WEEK LOW
6.32
MARKET CAP
901.17M
P/E (TTM)
-11.7107
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts
PR Newswire · 2d ago
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 11/24 13:12
The Daily Biotech Pulse:Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17)
Benzinga · 11/18 12:29
The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16)
Benzinga · 11/17 13:31
The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 5)
Benzinga · 11/06 12:47
Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that updated data from the Company's Phase 1 trial of axatilimab, its anti-CSF-1R monoclonal antibody, in patients with chronic graft versus host disease (cGVHD) will be featured during an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 5 – 8, 2020 in a virtual format.
PR Newswire · 11/04 21:05
Kura Oncology down 15% on KO-539 safety signals in early-stage study
Kura Oncology (KURA) slumps 15% premarket on light volume in apparent reaction to the release on an abstract on leukemia candidate KO-539 that will be presented at the American Society of Hematology
Seekingalpha · 11/04 14:04
Syndax Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 2, 2020 / Syndax Pharmaceuticals, Inc.
ACCESSWIRE · 11/02 19:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SNDX. Analyze the recent business situations of Syndax through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SNDX stock price target is 24.60 with a high estimate of 29.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 152
Institutional Holdings: 34.59M
% Owned: 84.64%
Shares Outstanding: 40.87M
TypeInstitutionsShares
Increased
28
3.04M
New
30
1.31M
Decreased
36
2.77M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Independent Director
Dennis Podlesak
President/Chief Operating Officer/Director
Michael Metzger
Chief Executive Officer/Director
Briggs Morrison
Chief Financial Officer/Chief Accounting Officer/Treasurer
Daphne Karydas
Senior Vice President/General Counsel/Secretary
Luke Albrecht
Senior Vice President
Michael Meyers
Chief Scientific Officer
Peter Ordentlich
Independent Director
Fabrice Egros
Independent Director
Jennifer Jarrett
Independent Director
Keith Katkin
Independent Director
Pierre Legault
Independent Director
William Meury
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, is a once-weekly, oral, small molecule, Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer. The Company’s clinical-stage product candidate, SNDX-5613, is the orally available, small molecule inhibitor of the interaction of menin with the mixed lineage leukemia protein (MLL). It is developing SNDX-5613 as a targeted therapy to treat two genetically defined acute leukemias: mixed lineage leukemia-rearranged (MLLr), and acute myeloid leukemia (AML), with a mutated nucleophosmin 1. It is also developing SNDX-6352, a monoclonal antibody targeting the colony stimulating factor-1 receptor.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Syndax Pharmaceuticals Inc stock information, including NASDAQ:SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.